Jenne Kyle's Form 4 filing
Ionis Pharmaceuticals Inc (IONS) · filed Apr 17, 2026
- Accession no.
- 0000874015-26-000171
- Filed
- Apr 17, 2026
- Trade date
- Apr 15-16, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $368.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jenne KyleCIK 0001791857 | Officer (EVP, Chf GL Pdt Str Ofcr) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | Common Stock | MOption exerciseAcquired | +12,226 | $0.00 | $0 | 28,615 | Direct | |
| Apr 16, 2026 | Common Stock | SSaleDisposed | −4,902 | $75.17 | −$368,483.34 | 23,713 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 15, 2026 | Common Stock | MOption exerciseDisposed | −12,226 | $0.00 | $0 | 74,402 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.